Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADPH oxidase 3 (NOX3)
- Target
- NOX3
- Molecular classification
- Enzyme, NADPH oxidase family, Oxidoreductase
01
Overview
NADPH oxidase 3 is a member of the NOX family of oxidoreductase enzymes that generate superoxide and other reactive oxygen species (ROS) by transporting electrons from NADPH across biological membranes. NOX3 is predominantly expressed in the inner ear, where it is critical for the formation of otoconia/otoliths necessary for the perception of gravity and normal vestibular function. Like other NOX family members, NOX3-derived ROS play roles in cellular signaling, regulation of gene expression, and cell differentiation. Mutations or dysregulation in NOX3 are linked to specific clinical phenotypes, such as drug-induced hearing loss and disorders of immune defense. While the NOX family is implicated in a range of ROS-driven diseases, selective pharmacological targeting of NOX3 specifically is limited, and direct clinical biomarkers or therapies are not yet established.
- Other names
- NOX3MOX2MOX-2GP91-3Mitogenic oxidase 2gp91phox homolog 3NADPH oxidase catalytic subunit-like 3
02
Mechanism of action
Inhibition of NADPH oxidase activity to decrease ROS production (observed with pan-NOX inhibitors)
03
Biological functions
Generation of reactive oxygen species (ROS)Electron transport across membranesCellular signalingRegulation of gene expressionCell differentiationBiogenesis of otoconia/otolith in the inner ear
04
Disease associations
Hearing loss (especially drug-induced hearing loss)Phagocyte bactericidal dysfunctionPotential involvement in neurodegenerative disease and other ROS-related disorders
05
Safety considerations
Inhibition of NOX enzymes can potentially impair physiological ROS signaling, affecting host defense and inner ear function (increased risk of infection, impact on hearing)
06
Interacting drugs
No highly selective drugs against NOX3 are approved; pan-NOX inhibitors (e.g., VAS2870, GKT137831) target multiple NOX isoforms and have shown effects on NOX3 in preclinical research
07
Biomarkers
No specific clinical biomarkers established for NOX3 activity; possible use of ROS or downstream oxidative stress markers in related research contexts but not in clinical routine
Beyond the preview
Go deeper on NADPH oxidase 3 (NOX3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NADPH oxidase 3 (NOX3).